Recently, significant progress has been achieved in the use of immunotherapy for hematological tumors, providing new hope for patients with brain tumors. Nevertheless, clinical practice has demonstrated that the use of single-agent immunotherapy has not produced substantial improvements in the prognosis of patients with brain tumors. An increasing number of researchers are attempting combination therapies, including radiotherapy, chemotherapy, and Tumor-Treating Fields (TTF) treatment combined with immunotherapy, to treat brain tumors. Although combination therapy represents a significant breakthrough in immunotherapy for brain tumors, it is still in the exploratory phase. Therefore, additional research is necessary to explore this field further. Meanwhile, treatment response assessment is another vital issue that remains to be further addressed in the clinical practice of immunotherapy of brain tumors, which can contribute to providing personalized therapies for patients.
In this research topic, we would like to identify innovative therapeutic approaches for patients with brain tumors, including novel immunotherapies, neoadjuvant therapy, CAR cells, oncolytic virotherapy, and others, to improve patient prognosis. Additionally, the potential molecular mechanism associated with tumour immunity is another critical issue requires to be explored in this topic. The identified genes can be served as treatment targets in the future. Furthermore, we also want to find some useful predictors and/or built models to early forecast the treatment response of patients who received immunotherapies, which can promote the precision medicine of brain tumors.
We welcome contributions from authors who are committing to improving immunotherapies in patients with brain tumors, whether this be novel immunotherapies, neoadjuvant therapy, or combination therapy with the aim of boosting the anti-tumour immune response. Researches that are devoted to exploring the predictors of immunotherapy response are also needed, which includes immunological scoring scales, image-based methods, and gene expression profiles, etc. Contributions considered for this research topic include original articles, clinical trials and review articles focusing on:
1. Immunotherapies for gliomas
2. Immunotherapies for brain metastases
3. Immunotherapies for other malignancies
4. Targetable genes associated with oncoimmunology
5. Predictors of immunotherapy response
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: Brain tumour, Gliomas, Brain metastases, Immunotherapy, Immune response
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
